» Articles » PMID: 38444484

A Machine Learning Strategy to Mitigate the Inappropriateness of Procalcitonin Request in Clinical Practice

Overview
Journal Heliyon
Specialty Social Sciences
Date 2024 Mar 6
PMID 38444484
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: The aim of this study was to develop machine learning (ML) models to mitigate the inappropriate request of Procalcitonin (PCT) in clinical wards.

Material And Methods: We built six different ML models based on both demographical data, i.e., sex and age, and laboratory parameters, i.e., cell blood count (CBC) parameters, inclusive of monocyte distribution width (MDW), and C-reactive protein (CRP). The dataset included 1667 PCT measurements of different patients. Based on a PCT cut-off of 0.50 ng/mL, we found 1090 negative (65.4%) and 577 positive (34.6%) results. We performed a 70:15:15 train:validation:test splitting based on the outcome.

Results: Random Forest, Support Vector Machine and eXtreme Gradient Boosting showed optimal performances for predicting PCT positivity, with an area under the curve ranging from 0.88 to 0.89.

Conclusions: The ML models developed could represent a useful tool to predict PCT positivity, avoiding unusefulness PCT requests. ML models are based on laboratory tests commonly ordered together with PCT but have the great advantage to be easy to measure and low-cost.

Citing Articles

Clinical usefulness of presepsin and monocyte distribution width (MDW) kinetic for predicting mortality in critically ill patients in intensive care unit.

Agnello L, Ciaccio A, Del Ben F, Gambino C, Scazzone C, Giglia A Front Med (Lausanne). 2024; 11:1393843.

PMID: 38831992 PMC: 11144889. DOI: 10.3389/fmed.2024.1393843.

References
1.
Tong-Minh K, van der Does Y, Engelen S, de Jong E, Ramakers C, Gommers D . High procalcitonin levels associated with increased intensive care unit admission and mortality in patients with a COVID-19 infection in the emergency department. BMC Infect Dis. 2022; 22(1):165. PMC: 8860271. DOI: 10.1186/s12879-022-07144-5. View

2.
Giulia B, Luisa A, Concetta S, Bruna L, Chiara B, Marcello C . Procalcitonin and community-acquired pneumonia (CAP) in children. Clin Chim Acta. 2015; 451(Pt B):215-8. DOI: 10.1016/j.cca.2015.09.031. View

3.
Lippi G, Sanchis-Gomar F . Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities. World J Gastroenterol. 2018; 23(47):8283-8290. PMC: 5743499. DOI: 10.3748/wjg.v23.i47.8283. View

4.
Ferraro S, Panteghini M . The role of laboratory in ensuring appropriate test requests. Clin Biochem. 2017; 50(10-11):555-561. DOI: 10.1016/j.clinbiochem.2017.03.002. View

5.
Wirz Y, Meier M, Bouadma L, Luyt C, Wolff M, Chastre J . Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. Crit Care. 2018; 22(1):191. PMC: 6092799. DOI: 10.1186/s13054-018-2125-7. View